Senior Scientist - Allogenic CAR T cells
Research | South San Francisco, CA | Full Time
Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Founded and led by former Kite Pharma executives who bring unrivaled clinical development acumen in cell therapy, Allogene is well-positioned to further the potential of allogeneic cell therapy for patients.
Allogeneic CAR T therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. This approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for CAR T treatment. The Allogene portfolio includes 16 pre-clinical T cell therapy assets and UCART19, an allogeneic CAR T therapy currently in Phase 1 development for the treatment of acute lymphoblastic leukemia (ALL). Through its notable partnerships, Allogene leverages pioneering technology platforms, including TALEN® gene editing technology, to progress its portfolio of immuno-oncology therapies. Allogene, with headquarters in San Francisco, California, is a Two River portfolio company formed with one of the largest Series A financings in biotechnology from an investment consortium which includes TPG, Vida Ventures, BellCo Capital, the University of California Office of the Chief Investment Officer, and Pfizer. For more information, please visit www.allogene.com, follow @AllogeneTx on Twitter and LinkedIn.
Job Description and Responsibilities:
Allogene Therapeutics is seeking a highly motivated Senior Scientist to conduct preclinical studies to evaluate and improve the efficacy of allogeneic CAR T cell therapies. The candidate will provide scientific and technical expertise to study CAR T cells in the allogeneic environment and investigate modifications that enhance their persistence and activity. The ideal candidate is an individual who is excited to take on new challenges in a dynamic start-up environment.
- Design and execute in vitro and in vivo studies to understand allogeneic CAR T cell activity, GvHD and rejection.
- Investigate genetic modifications that may sustain the in vivo persistence of CAR T cells in the allogeneic environment.
- Contribute to a collaborative group effort to advance allogeneic CAR T cell therapies into solid tumors.
- Collaborate with the CAR T cell process development group to inform future manufacturing process improvements for allogeneic CAR T cells.
- Stay abreast of latest scientific and technology advancements in the field.
- Train and mentor other scientists and perform other duties as assigned.
- Present at group meetings and project team meetings.
- PhD or equivalent with 1-3 years of post-doctoral training in immunology with relevant experience in GvHD and allogeneic rejection preferred.
- Knowledge of cellular and molecular immunology
- Ability to design and execute studies to evaluate CAR T cell activity in vitro and in vivo, including syngeneic models.
- Hands-on experience in retroviral/lentiviral transduction of mouse and human T cells preferred.
- Knowledge and experience in gene editing technologies including CRISPR/Cas9. • Experience in immune cell isolation and characterization using flow cytometry.
- Pro-active attitude and strong desire to be part of a team working together to overcome obstacles.
- Strong oral presentation and communication skills.
- Candidates must be authorized to work in the U.S.
As an equal opportunity employer, Allogene Inc. is committed to a diverse workforce. Employment decisions regarding recruitment and selection will be made without discrimination based on race, color, religion, national origin, gender, age, sexual orientation, physical or mental disability, genetic information or characteristic, gender identity and expression, veteran status, or other non-job related characteristics or other prohibited grounds specified in applicable federal, state and local laws. In order to ensure reasonable accommodation for individuals protected by Section 503 of the Rehabilitation Act of 1973, the Vietnam Era Veterans' Readjustment Act of 1974, and Title I of the Americans with Disabilities Act of 1990, applicants who require accommodation in the job application process may email us through our careers website at www.allogene.com for assistance. For more information about equal employment opportunity protections, please view the ‘EEO is the Law’ poster.